CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $5.84B, above the global median of $1.15B
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.84BUSDvs all stocks (USD)
Revenue (TTM)
409.48MUSDvs all stocks (USD)
Profit Margin
-19.85%vs Diagnostics & Research peers
Beta
2.12xvs all stocks
52-Week Change
169.92%vs all stocks
Market Capitalization
5.84BUSDvs all stocks (USD)
Enterprise Value
5.78BUSDvs all stocks (USD)
Forward P/E
-122.95xvs Diagnostics & Research peers
Price to Sales (TTM)
14.27xvs Diagnostics & Research peers
Price to Book (MRQ)
12.82xvs Diagnostics & Research peers
Enterprise to Revenue
14.12xvs Diagnostics & Research peers
Enterprise to EBITDA
-52.66xvs Diagnostics & Research peers
Gross Margin
51.59%vs Diagnostics & Research peers
Profit Margin
-19.85%vs Diagnostics & Research peers
Operating Margin
-34.92%vs Diagnostics & Research peers
Return on Assets (TTM)
-12.93%vs Diagnostics & Research peers
Return on Equity (TTM)
-18.16%vs Diagnostics & Research peers
Revenue (TTM)
409.48MUSDvs all stocks (USD)
Revenue per Share (TTM)
6.74USDUpdated Jul 19, 2026Quarterly Revenue Growth
19.30%vs Diagnostics & Research peers
Gross Profit (TTM)
213.23MUSDvs all stocks (USD)
EBITDA (TTM)
-109.83MUSDvs all stocks (USD)
Net Income (TTM)
-81.28MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.31%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
-55.59MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-58.48MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Diagnostics & Research peers
Revenue
376.57MUSDFY2025 · Sep 30, 2025Cost of Goods Sold
185.57MUSDFY2025 · Sep 30, 2025Gross Profit
191.00MUSDFY2025 · Sep 30, 2025Operating Income
-136.26MUSDvs all stocks (USD)
Pre-tax Income
-76.95MUSDFY2025 · Sep 30, 2025Income Tax Expense
719.00KUSDFY2025 · Sep 30, 2025Net Income
-77.67MUSDFY2025 · Sep 30, 2025EBIT
-136.26MUSDFY2025 · Sep 30, 2025EBITDA (Income Statement)
-160.25MUSDFY2025 · Sep 30, 2025Research & Development
80.28MUSDFY2025 · Sep 30, 2025Selling, General & Administrative
246.98MUSDFY2025 · Sep 30, 2025Non-operating Interest Income
11.36MUSDFY2025 · Sep 30, 2025EPS (Basic)
-1.30USDFY2025 · Sep 30, 2025EPS (Diluted)
-1.30USDFY2025 · Sep 30, 2025Basic Shares Outstanding
59.81MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
59.81MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-77.67MUSDFY2025 · Sep 30, 2025Operating Cash Flow
1.59MUSDFY2025 · Sep 30, 2025Free Cash Flow
-26.41MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
185.43MUSDFY2025 · Sep 30, 2025Income Tax Paid
683.00KUSDFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-77.67MUSDFY2025 · Sep 30, 2025Depreciation & Amortization
24.85MUSDFY2025 · Sep 30, 2025Stock-based Compensation
64.46MUSDFY2025 · Sep 30, 2025Other Non-cash Items
2.18MUSDFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
-22.38MUSDFY2025 · Sep 30, 2025Change in Accounts Payable (CF)
9.33MUSDFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
815.00KUSDFY2025 · Sep 30, 2025Capital Expenditures
-28.00MUSDFY2025 · Sep 30, 2025Net Acquisitions
2.50MUSDFY2025 · Sep 30, 2025Purchase of Investments
-49.39MUSDFY2025 · Sep 30, 2025Sale of Investments
50.13MUSDFY2025 · Sep 30, 2025Net Investing Cash Flow
-24.76MUSDFY2025 · Sep 30, 2025Common Stock Repurchase
-16.00KUSDFY2025 · Sep 30, 2025Other Financing Charges
15.00MUSDFY2025 · Sep 30, 2025Net Financing Cash Flow
14.98MUSDFY2025 · Sep 30, 2025Shares Outstanding
62.15MSharesUpdated Jul 19, 2026Float Shares
55.37MSharesUpdated Jul 19, 2026Shares Short
13.95MSharesUpdated Jul 19, 2026Short Ratio
6.32daysvs all stocks
Short % of Shares Outstanding
28.74%vs all stocks
% Held by Insiders
1.20%vs all stocks
% Held by Institutions
124.31%vs all stocks
Total Cash (MRQ)
171.67MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.76USDUpdated Jul 19, 2026Total Debt (MRQ)
110.84MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2436xvs Diagnostics & Research peers
Current Ratio (MRQ)
2.70xvs Diagnostics & Research peers
Book Value per Share (MRQ)
7.32USDUpdated Jul 19, 2026Total Assets
641.86MUSDvs all stocks (USD)
Total Current Assets
332.97MUSDFY2025 · Sep 30, 2025Total Liabilities
168.90MUSDFY2025 · Sep 30, 2025Total Non-current Assets
308.89MUSDFY2025 · Sep 30, 2025Total Non-current Liabilities
77.50MUSDFY2025 · Sep 30, 2025Total Current Liabilities
91.41MUSDFY2025 · Sep 30, 2025Cash
32.68MUSDFY2025 · Sep 30, 2025Cash Equivalents
150.37MUSDFY2025 · Sep 30, 2025Cash & Cash Equivalents
183.05MUSDFY2025 · Sep 30, 2025Other Short-term Investments
49.38MUSDFY2025 · Sep 30, 2025Accounts Receivable
57.02MUSDFY2025 · Sep 30, 2025Inventory
28.31MUSDFY2025 · Sep 30, 2025Accounts Payable
11.09MUSDFY2025 · Sep 30, 2025Short-term Debt
13.82MUSDFY2025 · Sep 30, 2025Deferred Revenue
6.88MUSDFY2025 · Sep 30, 2025Other Current Liabilities
722.00KUSDFY2025 · Sep 30, 2025Long-term Debt
61.75MUSDFY2025 · Sep 30, 2025Other Non-current Liabilities
747.00KUSDFY2025 · Sep 30, 2025Common Stock (Book)
0.00USDFY2025 · Sep 30, 2025Retained Earnings
-1.32BUSDFY2025 · Sep 30, 2025Total Shareholders' Equity
472.96MUSDvs all stocks (USD)
52-Week Low
23.30USDUpdated Jul 19, 202652-Week High
105.47USDUpdated Jul 19, 202652-Week Change
169.92%vs all stocks
Beta
2.12xvs all stocks
50-Day MA
76.29USDUpdated Jul 19, 2026200-Day MA
49.60USDUpdated Jul 19, 2026Avg 10-Day Volume
1.46MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.01MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.36USDUpdated Jul 19, 2026Other Income / Expense
47.94MUSDFY2025 · Sep 30, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Diagnostic
Operating Cash Flow Rising While Current Assets Shrink
Operating cash flow has trended up for six years while the current assets behind it shrank.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.20
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $5.84B, above the global median of $1.15BNotable
Market cap (USD): 5,844,162,818Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
CSN Mineracao S.A.
Tier 1ProductionThroughput-Bound ConversionFlow
Fujian Wanchen Biotechnology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Ford Otomotiv Sanayi A.Ş.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shandong Sun Paper Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Joinn Laboratories China Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
SmartSens Technology (Shanghai) Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
Tube Investments of India Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRisk
ASR Microelectronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Acm Research Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Iteq Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCDebt Falling While Share Count Rises
Iovance Biotherapeutics, Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Sepax Technologies Inc.
3 interpretationsDebt Falling While Share Count RisesOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Debt Decrease With Cash Near Total Debt And Equity